^
Association details:
| Biomarker: | CUL1-BRAF fusion |
|---|---|
| Cancer: | Melanoma |
| Drug: | Zelboraf (vemurafenib) (BRAF inhibitor, BRAF V600E inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Genetic heterogeneity of BRAF fusion kinases in melanoma affects drug responses
Excerpt:
Heterogeneous patterns of drug response to RAF and MEK inhibitors of cell lines harboring BRAF fusions compared toBRAFV600E mutant lines....all tested cell lines carrying BRAF fusions were resistant to vemurafenib and dabrafenib, sharply distinguishing them from BRAFV600E mutant cell lines…
DOI:
10.1016/j.celrep.2019.09.009
